Asset
LINACLOTIDE
IRONWOOD PHARMACEUTICALS INC. CLASS A COMMON STOCK
Revenue
No revenue reported in loaded filings.
Clinical trials (7)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT03931785 | phase2 | completed | 2019-05-01 | 2020-02-26 | Ironwood Pharmaceuticals, Inc. | A Study of MD-7246 to Treat Abdominal Pain in Patients With Diarrhea-predominant Irritable Bowel Syndrome |
| NCT02837783 | phase4 | terminated | 2016-12-21 | 2018-10-31 | Ironwood Pharmaceuticals, Inc. | A Study of the Effect of Linaclotide on Abdominal Girth in Participants With Irritable Bowel Syndrome With Constipation (IBS-C) |
| NCT03573908 | phase3 | completed | 2018-06-20 | 2019-03-13 | Ironwood Pharmaceuticals, Inc. | A Trial of Linaclotide 290 μg in Patients With Irritable Bowel Syndrome With Constipation (IBS-C) |
| NCT00730171 | phase3 | completed | 2008-09-01 | 2012-03-01 | Ironwood Pharmaceuticals, Inc. | An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation |
| NCT00730015 | phase3 | completed | 2008-08-01 | 2009-08-01 | Ironwood Pharmaceuticals, Inc. | Trial of Linaclotide in Patients With Chronic Constipation |
FDA applications (0)
This company has no applications containing this asset.